Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic reviewCapsule Summary
Background: Systemic glucocorticoids are first-line treatment options for autoimmune blistering diseases; however, their long-term use is associated with significant toxicities. Objective: To evaluate the side effects of steroid-sparing agents and compare them with those of steroids. Methods: We sea...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | JAAD International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666328722000979 |
| _version_ | 1797988555385995264 |
|---|---|
| author | Faith A.P. Zeng Anna Wilson, MD, BMedRadSc Tabrez Sheriff, MD Dedee F. Murrell, MA, BMBCh, MD, FACD, DSc |
| author_facet | Faith A.P. Zeng Anna Wilson, MD, BMedRadSc Tabrez Sheriff, MD Dedee F. Murrell, MA, BMBCh, MD, FACD, DSc |
| author_sort | Faith A.P. Zeng |
| collection | DOAJ |
| description | Background: Systemic glucocorticoids are first-line treatment options for autoimmune blistering diseases; however, their long-term use is associated with significant toxicities. Objective: To evaluate the side effects of steroid-sparing agents and compare them with those of steroids. Methods: We searched Cochrane Reviews, Embase, MEDLINE, and Scopus between October 1978 and May 2020 using the keywords “bullous pemphigoid,” “pemphigus,” “autoimmune blistering diseases,” and “side effects.” A total of 31 randomized controlled trials and retrospective case series were critically appraised. Results: This review includes a total of 1685 patients with autoimmune blistering diseases, of whom 781 had bullous pemphigoid and 904 had either pemphigus vulgaris or pemphigus foliaceous. Limitations: A major limitation is that because adjuvants are generally used in combination with steroids, only 12 of the studies reviewed included a “steroid-only” arm to allow for a direct comparison of side effects. Additionally, there is inadequate literature and lack of standardized grade reporting of specific side effects of each steroid-sparing agent. Conclusion: In the future, researchers should consider implementing the Common Terminology Criteria for Adverse Events, version 5.0, for reporting of all side effects to allow for consistency and standardization. It would be useful to have an index similar to the Glucocorticoid Toxicity Index to quantify these side effects. |
| first_indexed | 2024-04-11T08:05:53Z |
| format | Article |
| id | doaj.art-64cc7c650d0a4d2990a8075fc1d6ce8d |
| institution | Directory Open Access Journal |
| issn | 2666-3287 |
| language | English |
| last_indexed | 2024-04-11T08:05:53Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JAAD International |
| spelling | doaj.art-64cc7c650d0a4d2990a8075fc1d6ce8d2022-12-22T04:35:34ZengElsevierJAAD International2666-32872022-12-0193343Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic reviewCapsule SummaryFaith A.P. Zeng0Anna Wilson, MD, BMedRadSc1Tabrez Sheriff, MD2Dedee F. Murrell, MA, BMBCh, MD, FACD, DSc3University of New South Wales, Faculty of Medicine, Sydney, AustraliaUniversity of New South Wales, Faculty of Medicine, Sydney, Australia; Department of Dermatology, St. George Hospital, Sydney, AustraliaUniversity of New South Wales, Faculty of Medicine, Sydney, Australia; Department of Dermatology, St. George Hospital, Sydney, AustraliaUniversity of New South Wales, Faculty of Medicine, Sydney, Australia; Department of Dermatology, St. George Hospital, Sydney, Australia; The George Institute for Global Health, Sydney, Australia; Correspondence to: Dedee F. Murrell, MA, BMBCh, MD, FACD, DSc, Department of Dermatology, St. George Hospital, Gray St., Kogarah, Sydney, NSW 2217, Australia.Background: Systemic glucocorticoids are first-line treatment options for autoimmune blistering diseases; however, their long-term use is associated with significant toxicities. Objective: To evaluate the side effects of steroid-sparing agents and compare them with those of steroids. Methods: We searched Cochrane Reviews, Embase, MEDLINE, and Scopus between October 1978 and May 2020 using the keywords “bullous pemphigoid,” “pemphigus,” “autoimmune blistering diseases,” and “side effects.” A total of 31 randomized controlled trials and retrospective case series were critically appraised. Results: This review includes a total of 1685 patients with autoimmune blistering diseases, of whom 781 had bullous pemphigoid and 904 had either pemphigus vulgaris or pemphigus foliaceous. Limitations: A major limitation is that because adjuvants are generally used in combination with steroids, only 12 of the studies reviewed included a “steroid-only” arm to allow for a direct comparison of side effects. Additionally, there is inadequate literature and lack of standardized grade reporting of specific side effects of each steroid-sparing agent. Conclusion: In the future, researchers should consider implementing the Common Terminology Criteria for Adverse Events, version 5.0, for reporting of all side effects to allow for consistency and standardization. It would be useful to have an index similar to the Glucocorticoid Toxicity Index to quantify these side effects.http://www.sciencedirect.com/science/article/pii/S2666328722000979autoimmune blistering diseasesbullous pemphigoidCTCAEglucocorticoidsGTIimmunosuppressants |
| spellingShingle | Faith A.P. Zeng Anna Wilson, MD, BMedRadSc Tabrez Sheriff, MD Dedee F. Murrell, MA, BMBCh, MD, FACD, DSc Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic reviewCapsule Summary JAAD International autoimmune blistering diseases bullous pemphigoid CTCAE glucocorticoids GTI immunosuppressants |
| title | Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic reviewCapsule Summary |
| title_full | Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic reviewCapsule Summary |
| title_fullStr | Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic reviewCapsule Summary |
| title_full_unstemmed | Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic reviewCapsule Summary |
| title_short | Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic reviewCapsule Summary |
| title_sort | side effects of steroid sparing agents in patients with bullous pemphigoid and pemphigus a systematic reviewcapsule summary |
| topic | autoimmune blistering diseases bullous pemphigoid CTCAE glucocorticoids GTI immunosuppressants |
| url | http://www.sciencedirect.com/science/article/pii/S2666328722000979 |
| work_keys_str_mv | AT faithapzeng sideeffectsofsteroidsparingagentsinpatientswithbullouspemphigoidandpemphigusasystematicreviewcapsulesummary AT annawilsonmdbmedradsc sideeffectsofsteroidsparingagentsinpatientswithbullouspemphigoidandpemphigusasystematicreviewcapsulesummary AT tabrezsheriffmd sideeffectsofsteroidsparingagentsinpatientswithbullouspemphigoidandpemphigusasystematicreviewcapsulesummary AT dedeefmurrellmabmbchmdfacddsc sideeffectsofsteroidsparingagentsinpatientswithbullouspemphigoidandpemphigusasystematicreviewcapsulesummary |